Perspectives on lantibiotic discovery – where have we failed and what improvements are required?

Bibliography

• European centre for disease prevention and control/European medicine agency joint technical report. The bacterial challenge: Time to react. Press Release 2009. doi 10.2900/2518
   Google Scholar
• Oman TJ, van der Donk WA. Follow the leader: the use of leader peptides to guide natural product biosynthesis. Nat Chem Biol 2010;6(1):9-18
   PubMed Web of Science ®Google Scholar
• Allgaier H, Jung G, Werner RG, et al. Epidermin: sequencing of a heterodet tetracyclic 21-peptide amide antibiotic. Eur J Biochem 1986;160:9-22
   PubMedGoogle Scholar
• Schnell N, Entian KD, Schneider U, et al. Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature 1988;333(6170):276-8
   PubMed Web of Science ®Google Scholar
• Götz F, Perconti S, Popella P, et al. Epidermin and gallidermin: staphylococcal lantibiotics. Int J Med Microbiol 2014;304(1):63-71
   PubMed Web of Science ®Google Scholar
• Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Disc 2007;6(1):29-40
   PubMed Web of Science ®Google Scholar
• Dischinger J, Chipalu SB, Bierbaum G. Lantibiotics: promising candidates for future applications in health care. Int J Med Microbiol 2014;304(1):51-62
   PubMed Web of Science ®Google Scholar
• Pag U, Sahl HG. Multiple activities in lantibiotics - models for the design of novel antibiotics? Curr Pharm Des 2002;8(9):815-33
   PubMed Web of Science ®Google Scholar
• Brötz H, Josten M, Wiedemann I, et al. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 1998;30(2):317-27
   PubMed Web of Science ®Google Scholar
• Hasper HE, Kramer NE, Smith JL, et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid ii. Science 2006;313(5793):1636-7
   PubMed Web of Science ®Google Scholar
• Boakes S, Wadman S. The therapeutic potential of lantibiotics. Drug Dis Devel 2008;27:22-5
   Google Scholar
• Nascimento JS, Ceotto H, Nascimento SB, et al. Bacteriocins as alternative agents for control of multiresistant staphylococcal strains. Lett Appl Microbiol 2006;42:215-21
   PubMed Web of Science ®Google Scholar
• Fontana MB, Bastos MC, Brandelli A. Bacteriocins pep5 and epidermin inhibit staphylococcus epidermidis adhesion to catheters. Curr Microbiol 2006;52:350-3
   PubMed Web of Science ®Google Scholar
• Kruszewska D, Sahl HG, Bierbaum G, et al. Mersacidin eradicates methicillin-resistant staphylococcus aureus (mrsa) in a mouse rhinitis model. J Antimicrob Chemother 2004;54(3):648-53
   PubMed Web of Science ®Google Scholar
• Lubelski J, Rink R, Khusainov R, et al. Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin. Cell Mol Life Sci 2008;65(3):455-76
   PubMed Web of Science ®Google Scholar
• Mattick AT, Hirsch A, Berridge NJ. Further observations on an inhibitory substance (nisin) from lactic streptococci. Lancet 1947;250(6462):5-8
   Google Scholar
• Ghobrial O, Derendorf H, Hillman JD. Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic mu1140. J Pharm Sci 2010;99(5):2521-8
   PubMed Web of Science ®Google Scholar
• Ghobrial OG, Derendorf H, Hillman JD. Pharmacodynamic activity of the lantibiotic mu1140. Int J Antimicrob Agents 2009;33(1):70-4
   PubMed Web of Science ®Google Scholar
• Jabes D, Brunati C, Candiani G, et al. Efficacy of the new lantibiotic nai-107 in experimental infections induced by multidrug-resistant gram-positive pathogens. Antimicrob Agents Chemother 2011;55(4):1671-6
   PubMed Web of Science ®Google Scholar
• Crowther GS, Baines SD, Todhunter SL, et al. Evaluation of nvb302 versus vancomycin activity in an in vitro human gut model of clostridium difficile infection. J Antimicrob Chemother 2013;68(1):168-76
   PubMed Web of Science ®Google Scholar
• Jones A, Helm J. Emerging treatments in cystic fibrosis. Drugs 2009;69(14):1903-10
   PubMed Web of Science ®Google Scholar
• Tagg J, Dajani A, Wannamaker L. Bacteriocins of gram-positive bacteria. Bacteriol Rev 1976;40(3):722-56
   PubMedGoogle Scholar
• Tagg JR, Bannister LV. “Fingerprinting” beta-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. J Med Microbiol 1979;12(4):397-411
   PubMed Web of Science ®Google Scholar
• Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria. Microbiol Rev 1995;59:171-200
   PubMedGoogle Scholar
• Zhu H, Sandiford S, Wezel G. Triggers and cues that activate antibiotic production by actinomycetes. J Ind Microbiol Biotechnol 2014;41(2):371-86
   PubMed Web of Science ®Google Scholar
• Kies S, Vuong C, Hille M, et al. Control of antimicrobial peptide synthesis by the agr quorum sensing system in staphylococcus epidermidis: activity of the lantibiotic epidermin is regulated at the level of precursor peptide processing. Peptides 2003;24:329-38
   PubMed Web of Science ®Google Scholar
• Kuipers OP, Beerthuyzen MM, de Ruyter PG, et al. Autoregulation of nisin biosynthesis in lactococcus lactis by signal transduction. J Biol Chem 1995;270(45):27299-304
   PubMed Web of Science ®Google Scholar
• Schmitz S, Hoffmann A, Szekat C, et al. The lantibiotic mersacidin is an autoinducing peptide. Appl Environ Microbiol 2006;72(11):7270-7
   PubMed Web of Science ®Google Scholar
• Perez R, Zendo T, Sonomoto K. Novel bacteriocins from lactic acid bacteria (lab): various structures and applications. Microb Cell Fact 2014;13(Suppl 1):S3
   PubMed Web of Science ®Google Scholar
• Zendo T, Nakayama J, Fujita K, et al. Bacteriocin detection by liquid chromatography/mass spectrometry for rapid identification. J Appl Microbiol 2008;104(2):499-507
   PubMed Web of Science ®Google Scholar
• Li J, Girard G, Florea BI, et al. Identification and isolation of lantibiotics from culture: a bioorthogonal chemistry approach. Org Biomol Chem 2012;10(43):8677-83
   PubMed Web of Science ®Google Scholar
• Smith L, Novák J, Rocca J, et al. Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics. Eur J Biochem 2000;267(23):6810-16
   PubMedGoogle Scholar
• Begley M, Cotter PD, Hill C, et al. Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for lanM proteins. Appl Environ Microbiol 2009;75(17):5451-60
   PubMed Web of Science ®Google Scholar
• van Heel AJ, de Jong A, Montalbán-López M, et al. Bagel3: Automated identification of genes encoding bacteriocins and (non-)bactericidal posttranslationally modified peptides. Nucleic Acids Res 2013;41(W1):W448-53
   PubMed Web of Science ®Google Scholar
• Blin K, Medema MH, Kazempour D, et al. Antismash 2.0–a versatile platform for genome mining of secondary metabolite producers. Nucleic Acids Res 2013;41(W1):W204-12
   PubMed Web of Science ®Google Scholar
• Hammami R, Zouhir A, Le Lay C, et al. Bactibase second release: a database and tool platform for bacteriocin characterization. BMC Microbiol 2010;10(1):22
   PubMed Web of Science ®Google Scholar
• De La Fuente R, Sonawane ND, Arumainayagam D, et al. Small molecules with antimicrobial activity against e. Coli and p. Aeruginosa identified by high-throughput screening. Br J Pharmacol 2006;149(5):551-9
   PubMed Web of Science ®Google Scholar
• Ymele-Leki P, Cao S, Sharp J, et al. A high-throughput screen identifies a new natural product with broad-spectrum antibacterial activity. PLoS One 2012;7(2):e31307
   PubMed Web of Science ®Google Scholar
• Castiglione F, Lazzarini A, Carrano L, et al. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem Biol 2008;15(1):22-31
   PubMed Web of Science ®Google Scholar
• Castiglione F, Cavaletti L, Losi D, et al. A novel lantibiotic acting on bacterial cell wall synthesis produced by the uncommon actinomycete planomonospora sp. Biochemistry 2007;46(20):5884-95
   PubMed Web of Science ®Google Scholar
• Rollema HS, Kuipers OP, Both P, et al. Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol 1995;61(8):2873-8
   PubMed Web of Science ®Google Scholar
• Field D, Begley M, O’Connor PM, et al. Bioengineered nisin a derivatives with enhanced activity against both gram positive and gram negative pathogens. PLoS One 2012;7(10):e46884
   PubMed Web of Science ®Google Scholar
• Mothia B, Appleyard AN, Wadman S, et al. Synthesis of peptides containing overlapping lanthionine bridges on the solid phase: an analogue of rings d and e of the lantibiotic nisin. Org Lett 2011;13(16):4216-19
   PubMed Web of Science ®Google Scholar
• Liu W, Chan AS, Liu H, et al. Solid supported chemical syntheses of both components of the lantibiotic lacticin 3147. J Am Chem Soc 2011;133(36):14216-19
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhang ZZ, Chen XZ, et al. Site directed mutagenesis of the hinge region of nisin z and properties of nisin z mutants. Appl Microbiol Biotechnol 2004;64:806-15
   PubMed Web of Science ®Google Scholar
• Appleyard AN, Choi S, Read DM, et al. Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol 2009;16(5):490-8
   PubMed Web of Science ®Google Scholar
• Bonelli RR, Schneider T, Sahl HG, et al. Insights into in vivo activities of lantibiotics from gallidermin and epidermin mode of action studies. Antimicrob Agents Chemother 2006;50:1449-57
   PubMed Web of Science ®Google Scholar
• van Heel AJ, Mu D, Montalbán-López M, et al. Designing and producing modified, new-to-nature peptides with antimicrobial activity by use of a combination of various lantibiotic modification enzymes. ACS Synthetic Biology 2013;2(7):397-404
   PubMed Web of Science ®Google Scholar
• Arnusch CJ, Bonvin AM, Verel AM, et al. The vancomycin-nisin(1-12) hybrid restores activity against vancomycin resistant enterococci. Biochemistry 2008;47(48):12661-3
   PubMed Web of Science ®Google Scholar
• Whitehead HR. A substance inhibiting bacterial growth, produced by certain strains of lactic streptococci. Biochem J 1933;27(6):1793-800
   PubMedGoogle Scholar
• Jansen EF, Hirschmann DJ. Subtilin. An antibacterial product of bacillus subtilis. Culturing conditions and properties. Arch Biochem Biophys 1944;4:297-309
   Google Scholar
• Fuchs SW, Jaskolla T, Bochmann S, et al. Entianin, a novel subtilin-like lantibiotic from bacillus subtilis subsp. Spizizenii dsm 15029t with high antimicrobial activity. Appl Environ Microbiol 2011;77(5):1698-707
   PubMed Web of Science ®Google Scholar
• Hillman JD, Novák J, Sagura E, et al. Genetic and biochemical analysis of mutacin 1140, a lantibiotic from streptococcus mutans. Infect Immun 1998;66(6):2743-9
   PubMed Web of Science ®Google Scholar
• Georgalaki MD, Van den Berghe E, Kritikos D, et al. Macedocin, a food-grade lantibiotic produced by streptococcus macedonicus aca-dc 198. Appl Environ Microbiol 2002;68(12):5891-903
   PubMed Web of Science ®Google Scholar
• Ross KF, Ronson CW, Tagg JR. Isolation and characterization of the lantibiotic salivaricin a and its structural gene sala from streptococcus salivarius 20p3. Appl Environ Microbiol 1993;59(7):2014-21
   PubMed Web of Science ®Google Scholar
• Lawton EM, Cotter PD, Hill C, et al. Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile bacillus halodurans c-125. FEMS Microbiol Lett 2007;267(1):64-71
   PubMed Web of Science ®Google Scholar